Successful treatment with sorafenib in patients with advanced hepatocellular carcinoma: clinical case

Multi-kinase inhibitor sorafenib is the only one drug which increases life time in patients with advanced hepatocellular carcinoma (HCC). Results from the SHARP trial showed that median progression-free survival was less than 5 months. However, it is possible to achieve strong treatment effect for s...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Yu V Bisovskaya, V V Breder, B M Medvedeva, V A Gorbunova
Materialtyp: Artigo
Språk:Russo
Publicerad: IP Habib O.N. 2014-06-01
Serie:Современная онкология
Ämnen:
hepatocellular carcinoma
sorafenib
chronic hepatitis b
lamivudine
Länkar:https://modernonco.orscience.ru/1815-1434/article/view/26969
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk